PDSA cycle | Date at which completed | No of patients | Nominal increase | Predicted percentage increase (%) | Percentage increase (%) | Nature of intervention |
Baseline | 7/10/20 | 171 | – | – | – | Baseline measurement |
1 | 25/11/20 | 185 | 14 | 8.0 | 8.2 | Directly contacting baseline patient population by telephone |
2 | 9/12/20 | 194 | 9 | 7.0 | 5.3 | Creating EPR patient prompts on individual patient records |
3 | 10/2/21 (proposed) | – | – | 7.2 | – | Proposed patient focus groups and leaflet distribution |
Overall | 10/2/21 | 194 | 23 | 22.2 | 13.5 | – |
Table 1 showing our interventions increased the number of patients that have undergone a serum PSA measurement and corresponding percentage increase. There was an overall increase in 13.5% in high-risk patients that underwent a PSA measurement following our interventions. PDSA-3 was unable to be completed due to COVID-19 restrictions.
EPR, electronic-patient-record; PDSA, plan-do-study-act; PSA, prostate-specific antigen.